RE:Pfizer response to questions on M&A -> add value to companyNovember 01, 2022 - Pfizer reports on Q3 earnings Financial guidance for full-year 2022 does not assume the completion of any business development transactions not completed as of October 2, 2022, except for the acquisitions of Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) and Global Blood Therapeutics, Inc., which closed in the first week of October 2022, as well as signed transactions, if any, through mid-October 2022, which are expected to give rise to acquired in-process R&D (IPR&D) expenses during fiscal 2022.
https://www.biospace.com/article/releases/pfizer-reports-strong-third-quarter-2022-results-and-raises-2022-outlook/
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “I continue to be proud of our colleagues’ excellence, ingenuity and unwavering commitment to bringing breakthroughs to patients. Over the next 18 months, we expect to have up to 19 new products or indications in the market – including the five for which we have already begun co-promotion or commercialization earlier this year. Many of these 19 programs are already largely de-risked from a clinical perspective. ... [ ...perhaps Bourla is also referring to ONCY's IMMUNE MOLECULE PLATFORM TECHNOLOGY pelareorep - which has concluded the assessment of the Bracelet-1 Phase 2 clinical trial data effective October 31, 2022. ]